Overview
Neurofibromatosis type 2 (NF2) is a rare, inherited disorder that predisposes individuals to develop multiple benign (non‑cancerous) tumors of the nervous system, most commonly schwannomas on the vestibular (balance) nerve. These tumors can affect hearing, balance, vision, and other neurologic functions. NF2 is distinct from the more common neurofibromatosis type 1 (NF1); while NF1 is characterized by skin findings such as café‑au‑lait spots, NF2’s hallmark is bilateral vestibular schwannomas.
- Prevalence: Approximately 1 in 25,000‑33,000 people worldwide (≈0.003–0.004%)[1][2].
- Age of onset: Symptoms typically appear in late childhood or early adolescence, with a median diagnosis age of 18–20 years.
- Gender: Both sexes are equally affected.
- Inheritance: Autosomal‑dominant; a single mutated copy of the NF2 gene on chromosome 22 is sufficient to cause disease. About 50 % of cases are de‑new (no family history).
Symptoms
Because NF2 involves multiple cranial and spinal nerves, the clinical picture can be variable. Below is a comprehensive list of the most frequent manifestations, grouped by organ system.
Ear, Balance, and Hearing
- Bilateral vestibular schwannomas (acoustic neuromas): The primary feature; causes hearing loss, tinnitus (ringing), and disequilibrium.
- Unilateral or asymmetric hearing loss: May be the first clue in children.
- Vertigo or imbalance: Result of nerve compression.
Vision
- Posterior subcapsular cataracts: Occur in 60‑80 % of patients, often before age 30.
- Retinal hamartomas or optic nerve gliomas: Can lead to visual field defects.
- Glaucoma & ocular hypertension: Secondary to tumor pressure.
Skin and Soft Tissue
- Cutaneous schwannomas: Small, firm nodules often on the extremities.
- Subcutaneous or intradermal neurofibromas: Less numerous than in NF1.
Spinal Cord and Peripheral Nerves
- Spinal schwannomas & meningiomas: May cause back pain, radiculopathy, or weakness.
- Peripheral nerve sheath tumors: Can produce numbness or motor deficits.
Other Neurologic Symptoms
- Headaches: Frequently due to intracranial pressure changes.
- Facial nerve palsy: When facial nerve schwannomas develop.
- Trigeminal neuralgia: Sharp facial pain from tumor compression.
- Seizures: Rare, often linked to cortical dysplasia or meningioma.
Systemic Features
- Hearing aid or cochlear implant use: Required in many adults.
- Learning difficulties or developmental delay: More common in children with early‑onset disease.
Causes and Risk Factors
The root cause of NF2 is a mutation in the NF2 tumor‑suppressor gene, which encodes a protein called merlin (or schwannomin). Merlin helps regulate cell growth; loss of its function leads to uncontrolled proliferation of Schwann cells, meningothelial cells, and other supportive tissues.
Genetic Causes
- Inherited mutation: An affected parent passes the defective gene to 50 % of offspring (autosomal dominant).
- De‑novo mutation: Approximately half of NF2 cases arise from a new mutation in the germ line of a parent or early in embryonic development.
- Type of mutation: Truncating mutations (nonsense or frameshift) generally cause more severe disease than missense mutations.
Risk Factors
- Having a parent with NF2.
- Being male or female – no sex predisposition.
- Certain ethnic groups show slightly higher reported rates, but data are limited.
Diagnosis
Early diagnosis is crucial because timely intervention can preserve hearing and vision. Diagnosis relies on a combination of clinical criteria, imaging, and genetic testing.
Clinical Criteria (Manchester & NIH)
- Bilaterally diagnosed vestibular schwannomas.
- Any unilateral vestibular schwannoma plus at least two of the following: meningioma, glioma, cataract, cutaneous schwannoma, or a first‑degree relative with NF2.
- Typical familial pattern with a documented NF2 mutation.
Imaging Studies
- MRI of the brain with gadolinium: Gold standard for detecting vestibular schwannomas, meningiomas, and ependymomas.
- High‑resolution temporal bone MRI: Evaluates internal auditory canals.
- Spinal MRI: Screens for spinal tumors, especially if back pain or neurologic deficits are present.
- CT scan: Occasionally used for bone involvement or when MRI contraindicated.
Genetic Testing
- Sequencing of the NF2 gene from blood or saliva confirms the diagnosis in 95 % of cases.
- Important for family planning and cascade testing of at‑risk relatives.
Audiologic and Ophthalmologic Evaluation
- Baseline pure‑tone audiometry and speech‑in‑noise testing.
- Comprehensive eye exam, including slit‑lamp assessment for cataracts.
Treatment Options
Treatment is individualized, aiming to control tumor growth while preserving function. A multidisciplinary team—neuro‑otology, neurosurgery, ophthalmology, genetics, and rehabilitation—is recommended.
Observation (Watchful Waiting)
- Small, asymptomatic vestibular schwannomas (<1.5 cm) may be monitored with serial MRI every 6–12 months.
- Regular audiograms help detect early hearing decline.
Surgical Management
- Microsurgical removal: Indicated for large (>3 cm), rapidly growing, or symptomatic tumors. Approaches include translabyrinthine (sacrifices hearing) and retrosigmoid (potential hearing preservation).
- Debulking of spinal tumors: Alleviates cord compression, often combined with stabilization.
- Risks: facial nerve injury, cerebrospinal fluid leak, postoperative hearing loss.
Radiation Therapy
- Gamma Knife® or stereotactic radiosurgery (SRS): Delivers focused radiation to halt tumor growth; suitable for tumors 1–3 cm in size.
- Fractionated stereotactic radiotherapy (FSRT): Used when tumors encroach on critical structures.
- Long‑term data suggest stable hearing in 40‑60 % of treated ears.
Medical Therapies
- Bevacizumab (Avastin): An anti‑VEGF monoclonal antibody that can shrink vestibular schwannomas and improve hearing in ~30‑40 % of patients; administered intravenously every 2–3 weeks.
- MEK inhibitors (e.g., Selumetinib): Investigational; early trials show tumor size reduction.
- Supportive drugs: analgesics, antiepileptics, or steroids for symptom control.
Lifestyle & Supportive Measures
- Hearing aids, assistive listening devices, or cochlear implants after tumor removal.
- Low‑vision aids and regular ophthalmology follow‑up.
- Physical therapy for balance issues.
- Genetic counseling for patients and families.
Living with Neurofibromatosis Type 2
While NF2 is a chronic condition, many individuals lead productive lives with proper management.
Daily Management Tips
- Schedule regular surveillance: MRI brain & spine every 1–2 years, audiograms annually, eye exams every 1–2 years.
- Protect hearing: Avoid prolonged exposure to loud noises; use ear protection when necessary.
- Balance training: Tai‑chi, yoga, or vestibular rehabilitation can reduce fall risk.
- Skin care: Inspect cutaneous schwannomas for rapid change; report new growths to your clinician.
- Emotional health: Connect with NF2 support groups (e.g., the Acoustic Neuroma Association) and consider counseling.
- Education & work accommodations: Request assistive technologies, flexible scheduling, or remote work if hearing or vision impairment interferes.
Family Planning
- Pre‑implantation genetic diagnosis (PGD) and prenatal testing are available for couples who wish to avoid transmitting the mutation.
- Discuss reproductive options with a genetic counselor early.
Prevention
Because NF2 is genetic, primary prevention (preventing the disease from occurring) is not possible. However, secondary prevention—early detection and intervention—can reduce complications.
- Family members of an affected individual should undergo genetic testing even if asymptomatic.
- Annual audiologic and ophthalmologic screening for at‑risk relatives allows prompt treatment of early tumors.
- Adopt a healthy lifestyle (balanced diet, regular exercise, smoking cessation) to support overall nerve health, though it does not alter the genetic defect.
Complications
If left untreated or inadequately managed, NF2 can lead to significant morbidity.
- Progressive hearing loss: May require cochlear implantation or result in total deafness.
- Vision loss: Cataracts, retinal lesions, or optic nerve involvement can cause blindness.
- Neurological deficits: Weakness, numbness, or paralysis from spinal cord compression.
- Facial nerve paralysis: Affects facial expression and eye closure, increasing infection risk.
- Hydrocephalus: Tumor blockage of CSF pathways may require shunt placement.
- Malignant transformation: Rare (<1 %); malignant peripheral nerve sheath tumors can arise from existing schwannomas.
- Psychosocial impact: Depression, anxiety, and social isolation are common and require attention.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe headache or neck stiffness (possible intracranial hemorrhage).
- Rapid loss of vision or sudden double vision.
- Sudden onset of profound hearing loss on the previously better ear.
- Acute weakness, numbness, or loss of coordination affecting one side of the body.
- Severe, unrelenting vertigo with vomiting or inability to stand.
- Signs of infection after surgery (fever, wound redness, drainage).
- Sudden facial droop or inability to close one eye.
References
- Mayo Clinic. “Neurofibromatosis type 2.” https://www.mayoclinic.org/diseases-conditions/neurofibromatosis-type-2. Accessed April 2024.
- National Institute of Neurological Disorders and Stroke (NINDS). “Neurofibromatosis Type 2 Fact Sheet.” https://www.ninds.nih.gov/Disorders/All-Disorders/Neurofibromatosis-Type-2-Information-Page. 2023.
- World Health Organization. “WHO Classification of Tumours of the Central Nervous System, 5th Edition.” 2022.
- Cleveland Clinic. “Neurofibromatosis Type 2 (NF2).” https://my.clevelandclinic.org/health/diseases/12669-neurofibromatosis-type-2. 2024.
- Plotkin SR, et al. “Bevacizumab for progressive vestibular schwannomas in NF2.” *New England Journal of Medicine*, 2020;382:1120‑1132.
- Stankovic KM, et al. “Management of neurofibromatosis type 2: Consensus statement of the International NF2 Consortium.” *Lancet Oncology*, 2022;23:e210‑e219.